Tracon's $200M Damages Claim Axed In Cancer Antibody Feud
An international tribunal has rejected a $200 million damages claim brought against a Chinese biotech company by California-based Tracon Pharmaceuticals following a dispute over a collaboration agreement to develop antibodies aimed...To view the full article, register now.
Already a subscriber? Click here to view full article